Federico Pollano Joins IDT Biologika As Chief Commercial Officer To Drive Global Growth

   IDT Biologika, a global leader in developing and manufacturing viral vaccines, gene therapies, and sterile injectables, has announced Federico Pollano as its new Chief Commercial Officer, starting March 1, 2025. Federico Pollano brings a wealth of experience from top roles in the pharmaceutical and biotech industries. Most recently, he served as Senior Vice President of Business Development at Rentschler Biopharma for seven years, where he led sales and customer service and joined the Extended Executive Board in 2023.

Federico Pollano expressed, “I am very much looking forward to my new role at IDT Biologika and especially to contributing my skills and dedication to this great team. IDT has already established itself as a reliable partner in the market and is currently experiencing growth alongside SK Bioscience. I am excited about contributing to this growth, particularly by strengthening and expanding relationships with customers and leveraging the full range of IDT’s capabilities to ensure the success of our clients’ projects.”

Before that, he played key roles in shaping CDMO businesses, including as Global Director of Contract Manufacturing and Business Development at Polpharma Biologics and Managing Director at Richter-Helm-BioTec. His earlier career included leadership positions in clinical research, health economics, licensing, and M&A projects at GSK and Ratiopharm. With his strong background and proven track record, Federico Pollano is well-positioned to drive IDT Biologika’s growth and strengthen its position as a trusted partner in the life sciences industry.

“In Federico Pollano, we have found an outstanding personality for this position, both personally and professionally. We want to strengthen our global network and strategically expand our business, and Federico Pollano’s many years of experience in the CDMO business will provide us with important inspiration,” commented Dr. Sally Choe, Co-CEO IDT Biologika.